Allogeneic Hematopoietic Cell Transplantation for Primary Refractory or Relapsed Hodgkin's and Non-Hodgkin's Lymphoma with B-cell or T-cell Origin (L39396) - R1 - Effective March 5, 2023

Date Posted: February 5, 2026

This Local Coverage Determination (LCD) has been revised under contractor numbers: 01112 (NCA), 01182 (SCA), 01212 (AS, GU, HI, and NMI), and 01312 (NV).

Effective Date: March 5, 2023

Summary of Changes:

COVERAGE INDICATIONS:

Revised sentence from "Per the NCD, "All other indications for stem cell transplantation not otherwise noted above as covered or non-covered remain at local Medicare Administrative Contractor (MAC) discretion.""to "Per the NCD, "Coverage of all other indications for stem cell transplantation not otherwise specified above as covered or non-covered will be made by local Medicare Administrative Contractors under sections 1862(a)(1)(A).""

ANALYSIS OF EVIDENCE:

Added the acronym transplant-related mortality (TRM)

Visit the Noridian Active LCDs webpage to view the Active LCD or access it via the CMS MCD.

Last Updated $dateUtil.getDate( $modifieddate , "MMM dd , yyyy" , $locale , $tzone )